Literature DB >> 23026271

Molecular basis of esophageal cancer development and progression.

Chadrick E Denlinger1, Robert K Thompson.   

Abstract

This article discusses the molecular basis of esophageal cancer development and subsequent progression of disease. Differing epidemiologic factors are associated with esophageal adenocarcinoma and squamous cell carcinoma. These 2 different histologic types have differing putative underlying mechanisms of transdifferentiation from normal esophageal mucosa to malignant histologies via gene dysregulation, biochemical modifications, and altered cell signaling pathways. Our developing understanding of the molecular events underlying esophageal cancer is leading to the establishment of identifiable biomarkers and the clinical use of molecularly targeted treatment agents. The identification of driving genetic mutations and altered signaling pathways has also had favorable outcomes.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026271     DOI: 10.1016/j.suc.2012.07.002

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  17 in total

1.  Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells.

Authors:  Xue Yang; Jee Hoon Song; Yulan Cheng; Wenjing Wu; Tushar Bhagat; Yiting Yu; John M Abraham; Sariat Ibrahim; William Ravich; Bani Chander Roland; Mouen Khashab; Vikesh K Singh; Eun Ji Shin; Xiao Yang; Amit K Verma; Stephen J Meltzer; Yuriko Mori
Journal:  Gut       Date:  2013-09-02       Impact factor: 23.059

2.  Expression of migfilin is increased in esophageal cancer and represses the Akt-β-catenin activation.

Authors:  Huan He; Fang Ding; Sheng Li; Hongyan Chen; Zhihua Liu
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

3.  Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.

Authors:  Weixin Zhao; Jianfeng Luo; Xuwei Cai
Journal:  Tumour Biol       Date:  2013-05-17

Review 4.  Gastroesophageal reflux disease and non-esophageal cancer.

Authors:  Fernando A M Herbella; Sebastião Pannocchia Neto; Ilka Lopes Santoro; Licia Caldas Figueiredo
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Glutathione S-transferase M1 null genotype contributes to increased risk of esophageal carcinoma in Chinese population.

Authors:  Shan Zhong; Wei Zhao; Chaojing Lu; Bailing Li; Yang Yuan; Danfeng Guo; Zhijie Chang; Binhua Jiao; Lixin Yang
Journal:  Tumour Biol       Date:  2013-04-28

Review 6.  Glutathione S-transferase M1 polymorphism and esophageal cancer risk: An updated meta-analysis based on 37 studies.

Authors:  Quan-Jun Lu; Ya-Cong Bo; Yan Zhao; Er-Jiang Zhao; Wolde Bekalo Sapa; Ming-Jie Yao; Dan-Dan Duan; Yi-Wei Zhu; Wei-Quan Lu; Ling Yuan
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

7.  Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.

Authors:  Xiaobin Cui; Zhimin Zhao; Dong Liu; Tao Guo; Su Li; Jianming Hu; Chunxia Liu; Lan Yang; Yuwen Cao; Jinfang Jiang; Weihua Liang; Wei Liu; Shugang Li; Lianghai Wang; Lidong Wang; Wenyi Gu; Chuanyue Wu; Yunzhao Chen; Feng Li
Journal:  J Exp Clin Cancer Res       Date:  2014-02-17

8.  Expression and Splice Variant Analysis of Human TCF4 Transcription Factor in Esophageal Cancer.

Authors:  Gang He; Xingying Guan; Xuedan Chen; Yan Wang; Chao Luo; Bo Zhang
Journal:  J Cancer       Date:  2015-02-15       Impact factor: 4.207

9.  LYN, a Key Gene From Bioinformatics Analysis, Contributes to Development and Progression of Esophageal Adenocarcinoma.

Authors:  Dabiao Liu
Journal:  Med Sci Monit Basic Res       Date:  2015-12-21

10.  Interaction of XRCC1 Arg399Gln Polymorphism and Alcohol Consumption Influences Susceptibility of Esophageal Cancer.

Authors:  Man Li; Xia Yu; Zhi-Yan Zhang; Chun-Long Wu; Hai-Long Xu
Journal:  Gastroenterol Res Pract       Date:  2016-02-01       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.